| scholarly article | Q13442814 |
| P50 | author | Salvatore Sutti | Q80421747 |
| Maurizio Parola | Q37841527 | ||
| Marco Vacchiano | Q52725528 | ||
| Simon McArthur | Q57004696 | ||
| Emanuele Albano | Q57720366 | ||
| Mauro Perretti | Q60976463 | ||
| P2093 | author name string | Elisabetta Bugianesi | |
| Chris Reutelingsperger | |||
| Dennis Kusters | |||
| Aastha Jindal | |||
| Cristina Bozzola | |||
| Stefania Bena | |||
| Claudia Paternostro | |||
| Irene Locatelli | |||
| P2860 | cites work | Galectin-3 regulates myofibroblast activation and hepatic fibrosis | Q24546358 |
| Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis | Q24649584 | ||
| Resolution of inflammation: an integrated view | Q26852569 | ||
| Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor | Q28193896 | ||
| Resolvin D1 binds human phagocytes with evidence for proresolving receptors | Q28270638 | ||
| Annexin A1 and glucocorticoids as effectors of the resolution of inflammation | Q28304897 | ||
| Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease | Q28534290 | ||
| Design and validation of a histological scoring system for nonalcoholic fatty liver disease | Q29614930 | ||
| Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis | Q29619888 | ||
| Therapeutic anti-inflammatory potential of formyl-peptide receptor agonists | Q30390321 | ||
| Endogenous annexin A1 counter-regulates bleomycin-induced lung fibrosis. | Q34051566 | ||
| Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation | Q34095174 | ||
| Galectin-3 deficiency prevents concanavalin A-induced hepatitis in mice | Q61903452 | ||
| Pathology of nonalcoholic fatty liver disease | Q83094715 | ||
| Annexin-1 regulates macrophage IL-6 and TNF via glucocorticoid-induced leucine zipper | Q84122777 | ||
| Increased adiposity, dysregulated glucose metabolism and systemic inflammation in Galectin-3 KO mice | Q34603941 | ||
| The regulation of inflammation by galectin-3. | Q34991925 | ||
| Increased adiposity in annexin A1-deficient mice | Q35061556 | ||
| Therapy of experimental NASH and fibrosis with galectin inhibitors | Q35075568 | ||
| Galectin-3 modulates phagocytosis-induced stellate cell activation and liver fibrosis in vivo | Q35780859 | ||
| Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2 | Q36042132 | ||
| Neutrophil secretion products pave the way for inflammatory monocytes | Q36104871 | ||
| Functional role of monocytes and macrophages for the inflammatory response in acute liver injury | Q36331567 | ||
| Annexin A1 and the regulation of innate and adaptive immunity. | Q36449551 | ||
| Role of galectin-3 in classical and alternative macrophage activation in the liver following acetaminophen intoxication | Q36456913 | ||
| Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair | Q36497289 | ||
| Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. | Q37064636 | ||
| Animal models of NASH: getting both pathology and metabolic context right | Q37254525 | ||
| The epidemiology of nonalcoholic fatty liver disease: a global perspective | Q37310275 | ||
| Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses. | Q37318064 | ||
| Hanging in the balance: endogenous anti-inflammatory mechanisms in tissue repair and fibrosis | Q38046124 | ||
| Attenuation of plasma annexin A1 in human obesity | Q39265423 | ||
| Pleiotropic regulation of macrophage polarization and tumorigenesis by formyl peptide receptor-2. | Q39557367 | ||
| Galectin-3 deficiency accelerates high-fat diet-induced obesity and amplifies inflammation in adipose tissue and pancreatic islets | Q40944709 | ||
| The required role of endogenously produced lipoxin A4 and annexin-1 for the production of IL-10 and inflammatory hyporesponsiveness in mice | Q43643070 | ||
| Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver. | Q45052723 | ||
| Annexin-1 modulates repair of gastric mucosal injury | Q46803364 | ||
| Proresolving and tissue-protective actions of annexin A1-based cleavage-resistant peptides are mediated by formyl peptide receptor 2/lipoxin A4 receptor. | Q48473101 | ||
| Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. | Q50528458 | ||
| Disrupted galectin-3 causes non-alcoholic fatty liver disease in male mice. | Q52574179 | ||
| Bias in macrophage activation pattern influences non-alcoholic steatohepatitis (NASH) in mice. | Q53092402 | ||
| Transcriptional profiling of human monocytes reveals complex changes in the expression pattern of inflammation-related genes in response to the annexin A1-derived peptide Ac1-25 | Q54250222 | ||
| Deficiency in galectin-3 promotes hepatic injury in CDAA diet-induced nonalcoholic fatty liver disease. | Q55692292 | ||
| Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis | Q61187743 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | steatohepatitis | Q2335423 |
| P304 | page(s) | 531-544 | |
| P577 | publication date | 2014-05-12 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Endogenous annexin A1 is a novel protective determinant in nonalcoholic steatohepatitis in mice | |
| P478 | volume | 60 |
| Q92074847 | Activation of Galectin-3 (LGALS3) Transcription by Injurious Stimuli in the Liver Is Commonly Mediated by BRG1 |
| Q52862706 | Activation of annexin A1 signalling in renal fibroblasts exerts antifibrotic effects. |
| Q90663594 | Adaptive immunity: an emerging player in the progression of NAFLD |
| Q64079991 | Advancements of Annexin A1 in inflammation and tumorigenesis |
| Q58778932 | Altered hepatic glucose homeostasis in AnxA6-KO mice fed a high-fat diet |
| Q26765186 | Annexin A1 and the Resolution of Inflammation: Modulation of Neutrophil Recruitment, Apoptosis, and Clearance |
| Q64243589 | Annexin A1 as Neuroprotective Determinant for Blood-Brain Barrier Integrity in Neonatal Hypoxic-Ischemic Encephalopathy |
| Q47585175 | Annexin A1 attenuates microvascular complications through restoration of Akt signalling in a murine model of type 1 diabetes. |
| Q57107763 | Annexin A1 in inflammation and breast cancer: a new axis in the tumor microenvironment |
| Q51249008 | Annexin A1 promotes timely resolution of inflammation in murine gout. |
| Q37591999 | Annexin A1 restores Aβ1-42 -induced blood-brain barrier disruption through the inhibition of RhoA-ROCK signaling pathway |
| Q91755992 | Annexin A1-mediated inhibition of inflammatory cytokines may facilitate the resolution of inflammation in acute radiation-induced lung injury |
| Q55292869 | Annexin A1: Uncovering the Many Talents of an Old Protein. |
| Q38846007 | Annexin A1: shifting the balance towards resolution and repair |
| Q64078784 | Annexin-A1: Therapeutic Potential in Microvascular Disease |
| Q92130001 | Annexins in Adipose Tissue: Novel Players in Obesity |
| Q38700498 | Delivery strategies to control inflammatory response: Modulating M1-M2 polarization in tissue engineering applications. |
| Q91739105 | Expression levels and prognostic values of annexins in liver cancer |
| Q53454163 | Fat-laden macrophages modulate lobular inflammation in nonalcoholic steatohepatitis (NASH). |
| Q99585981 | Formyl peptide receptor type 2 agonists to kick-start resolution pharmacology |
| Q40512525 | Gene Expression Patterns Associated With Histopathology in Toxic Liver Fibrosis. |
| Q89706481 | Hypoxia-inducible factor 2α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine-rich glycoprotein |
| Q64111533 | Identification of AnnexinA1 as an Endogenous Regulator of RhoA, and Its Role in the Pathophysiology and Experimental Therapy of Type-2 Diabetes |
| Q39067604 | Immune resolution mechanisms in inflammatory arthritis |
| Q91750082 | Increased liver localization of lipopolysaccharides in human and experimental non-alcoholic fatty liver disease |
| Q47305480 | Inflammation and renal fibrosis: Recent developments on key signaling molecules as potential therapeutic targets. |
| Q36095550 | Lipoxin A4 Attenuates Obesity-Induced Adipose Inflammation and Associated Liver and Kidney Disease |
| Q36294146 | Microvesicles released from fat-laden cells promote activation of hepatocellular NLRP3 inflammasome: A pro-inflammatory link between lipotoxicity and non-alcoholic steatohepatitis |
| Q38705659 | Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies |
| Q27303970 | Pharmacological Treatment with Annexin A1 Reduces Atherosclerotic Plaque Burden in LDLR-/- Mice on Western Type Diet |
| Q64972783 | Protective Effects of Licochalcone A Ameliorates Obesity and Non-Alcoholic Fatty Liver Disease Via Promotion of the Sirt-1/AMPK Pathway in Mice Fed a High-Fat Diet. |
| Q33794042 | SerpinB3 Promotes Pro-fibrogenic Responses in Activated Hepatic Stellate Cells. |
| Q30399200 | The histone methyltransferase Suv39h2 contributes to nonalcoholic steatohepatitis in mice. |
| Q39211384 | The significance of macrophage polarization subtypes for animal models of tissue fibrosis and human fibrotic diseases |
Search more.